Literature DB >> 21047731

EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.

Mélanie Héroult1, Florence Schaffner, Dennis Pfaff, Claudia Prahst, Robert Kirmse, Simone Kutschera, Maria Riedel, Thomas Ludwig, Peter Vajkoczy, Ralph Graeser, Hellmut G Augustin.   

Abstract

The tyrosine kinase receptor EphB4 interacts with its ephrinB2 ligand to act as a bidirectional signaling system that mediates adhesion, migration, and guidance by controlling attractive and repulsive activities. Recent findings have shown that hematopoietic cells expressing EphB4 exert adhesive functions towards endothelial cells expressing ephrinB2. We therefore hypothesized that EphB4/ephrinB2 interactions may be involved in the preferential adhesion of EphB4-expressing tumor cells to ephrinB2-expressing endothelial cells. Screening of a panel of human tumor cell lines identified EphB4 expression in nearly all analyzed tumor cell lines. Human A375 melanoma cells engineered to express either full-length EphB4 or truncated EphB4 variants which lack the cytoplasmic catalytic domain (ΔC-EphB4) adhered preferentially to ephrinB2-expressing endothelial cells. Force spectroscopy by atomic force microscopy confirmed, on the single cell level, the rapid and direct adhesive interaction between EphB4 and ephrinB2. Tumor cell trafficking experiments in vivo using sensitive luciferase detection techniques revealed significantly more EphB4-expressing A375 cells but not ΔC-EphB4-expressing or mock-transduced control cells in the lungs, the liver, and the kidneys. Correspondingly, ephrinB2 expression was detected in the microvessels of these organs. The specificity of the EphB4-mediated tumor homing phenotype was validated by blocking the EphB4/ephrinB2 interaction with soluble EphB4-Fc. Taken together, these experiments identify adhesive EphB4/ephrinB2 interactions between tumor cells and endothelial cells as a mechanism for the site-specific metastatic dissemination of tumor cells. AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21047731     DOI: 10.1158/1541-7786.MCR-09-0453

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  19 in total

Review 1.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

2.  Unraveling the Receptor-Ligand Interactions between Bladder Cancer Cells and the Endothelium Using AFM.

Authors:  Vinoth Sundar Rajan; Valérie M Laurent; Claude Verdier; Alain Duperray
Journal:  Biophys J       Date:  2017-03-28       Impact factor: 4.033

3.  Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.

Authors:  Yanyang Tu; Shiming He; Jianfang Fu; Gang Li; Ruxiang Xu; Hongliu Lu; Jianping Deng
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

4.  BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.

Authors:  Jai-Hyun Kim; Matthew R Peacock; Steven C George; Christopher C W Hughes
Journal:  Angiogenesis       Date:  2012-05-24       Impact factor: 9.596

5.  EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Authors:  Akil A Merchant; Aparna Jorapur; Amy McManus; Ren Liu; Valery Krasnoperov; Parvesh Chaudhry; Mohan Singh; Lisa Harton; Mary Agajanian; Miriam Kim; Timothy J Triche; Brian J Druker; Jeffrey W Tyner; Parkash S Gill
Journal:  Blood Adv       Date:  2017-08-28

Review 6.  Eph receptors and ephrins: therapeutic opportunities.

Authors:  Antonio Barquilla; Elena B Pasquale
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-03       Impact factor: 13.820

7.  ICAM1 depletion reduces spinal metastasis formation in vivo and improves neurological outcome.

Authors:  Thomas Broggini; Marcus Czabanka; Andras Piffko; Christoph Harms; Christian Hoffmann; Ralf Mrowka; Frank Wenke; Urban Deutsch; Carsten Grötzinger; Peter Vajkoczy
Journal:  Eur Spine J       Date:  2015-02-25       Impact factor: 3.134

8.  Ephrin B2 mediates high glucose induced endothelial-to-mesenchymal transition in human aortic endothelial cells.

Authors:  Cheng Yuan; Lihua Ni; Changjiang Zhang; Hao Xia; Xiaoyan Wu
Journal:  Cardiovasc Diagn Ther       Date:  2020-08

9.  Quantitative Proteomic Analysis of Small and Large Extracellular Vesicles (EVs) Reveals Enrichment of Adhesion Proteins in Small EVs.

Authors:  Lizandra Jimenez; Hui Yu; Andrew J McKenzie; Jeffrey L Franklin; James G Patton; Qi Liu; Alissa M Weaver
Journal:  J Proteome Res       Date:  2019-01-23       Impact factor: 4.466

10.  Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly.

Authors:  Dong Li; Tara L Wenger; Christoph Seiler; Michael E March; Alvaro Gutierrez-Uzquiza; Charlly Kao; Elizabeth Bhoj; Lifeng Tian; Misha Rosenbach; Yichuan Liu; Nora Robinson; Mechenzie Behr; Rosetta Chiavacci; Cuiping Hou; Tiancheng Wang; Marina Bakay; Renata Pellegrino da Silva; Jonathan A Perkins; Patrick Sleiman; Michael A Levine; Patricia J Hicks; Maxim Itkin; Yoav Dori; Hakon Hakonarson
Journal:  Hum Mol Genet       Date:  2018-09-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.